Skip to main content
SpringerLink
Log in

Stem Cell Transplantation for Hodgkin’s and Non-Hodgkin’s Lymphomas

  • Chapter
Stem Cell Transplantation for Hematologic Malignancies

Part of the book series: Contemporary Hematology ((CH))

  • 146 Accesses

Abstract

The role of high-dose therapy (HDT) and stem cell transplantation (SCT) in the treatment non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD) continues to evolve. There is considerably more experience with autologous SCT (autoSCT) than allogeneic SCT (alloSCT). AutoSCT has an established role in relapsed/refractory intermediate-grade NHL and relapsed/ refractory HD. Uncertainty still exists about the benefit of autoSCT as front-line therapy for high-risk NHL and HD and in indolent NHL. A11oSCT does not have a well-established role in NHL or HD, whereas reduced intensity alloSCT is under active investigation. Many questions remain to be answered regarding the optimal timing of SCT, ideal preparative regimen, best source of stem cells, role of stem-cell-purging procedures, and importance of pre-SCT cytoreduction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’ s disease after combination chemotherapy: the low probability of cure. J Clin Oncol 1992; 10: 210.

    PubMed  CAS  Google Scholar 

  2. Bonfante V, Santoro A, Vivani S, et al. Outcome of patients with Hodgkin’ s disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528.

    PubMed  CAS  Google Scholar 

  3. Bierman PJ, Bagin RG, Jagganath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 1993; 4: 767.

    PubMed  CAS  Google Scholar 

  4. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801.

    PubMed  CAS  Google Scholar 

  5. Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’ s disease. Blood 1997; 89: 814.

    PubMed  CAS  Google Scholar 

  6. Carella AM, Congui AM, Gaozza E, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin’s disease patients: an Italian study. J Clin Oncol 1988; 6: 1411.

    PubMed  CAS  Google Scholar 

  7. Reece D, Barnett M, Connors J, et al. Intensive chemotherapy with cyclophosphamide carmustine, and etoposide with autologous bone marrow for relapsed Hodgkin’s disease. J Clin Oncol 1991; 9: 1871.

    PubMed  CAS  Google Scholar 

  8. Armitage J, Bierman P, Vose J, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin’s disease. Am J Med 1991; 91: 605.

    Article  PubMed  CAS  Google Scholar 

  9. Chopra R, McMillan A, Linch D, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’ s disease: a single-center eight-year study of 155 patients. Blood 1993; 81: 1137.

    PubMed  CAS  Google Scholar 

  10. Yahalom J, Gulati S, Toia M, et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol 1993; 11: 1062.

    PubMed  CAS  Google Scholar 

  11. Rapoport A, Rowe J, Kouides P, et al. One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351.

    Google Scholar 

  12. Nademanee A, O’Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381.

    PubMed  CAS  Google Scholar 

  13. Sweetenham JW, Taghipour G, Milligan D, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Bone Marrow Transplant 1997; 20: 745.

    Article  PubMed  CAS  Google Scholar 

  14. Sureda A, Arranz R, Iriondo E, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Atológo de Médula Ósea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395.

    PubMed  CAS  Google Scholar 

  15. Lazarus HM, Loberiza FR, Zhang M-J, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001; 27: 387.

    Article  PubMed  CAS  Google Scholar 

  16. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616.

    Article  PubMed  CAS  Google Scholar 

  17. Argiris A, Seropian S, Cooper DL, et al. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin’s disease. Ann Oncol 2000; 11: 665.

    Article  PubMed  CAS  Google Scholar 

  18. Josting A, Katay I, Rueffer U, et al. Favorable outcome with relapsed or refractory Hodgkin’ s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage chemotherapy (Dexa-BEAM). Ann Oncol 1998; 9: 289.

    Article  PubMed  CAS  Google Scholar 

  19. Stewart DA, Guo D, Gluck S, et al. Double high-dose therapy for Hodgkin’ s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000; 26: 383.

    Article  PubMed  CAS  Google Scholar 

  20. Fermé C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’ s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Études des Lymphomes de l’Adulte H89 Trial. J Clin Oncol 2002; 20: 467.

    Article  PubMed  Google Scholar 

  21. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’ s disease: a randomized trial. Lancet 2002; 359: 2065.

    Google Scholar 

  22. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’ s disease: results of a BNLI randomized trial. Lancet 1993; 341: 1051.

    Article  PubMed  CAS  Google Scholar 

  23. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’ s disease: analysis of 280 patients from the French registry. Société Francaise de Greffe de Moëlle. Bone Marrow Transplant 1997; 20: 21.

    Article  PubMed  CAS  Google Scholar 

  24. Wheeler C, Eickhoff C, Elias A, et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3: 98.

    PubMed  CAS  Google Scholar 

  25. O’ Brien ME, Milan S, Cunningham D, et al. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin’s disease: a pragmatic prognostic index. Br J Cancer 1996; 73: 1272.

    Article  Google Scholar 

  26. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/ cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193.

    PubMed  CAS  Google Scholar 

  27. Fung H, Nademanee A, Kashyap, et al. Evaluation of prognostic factors in patients with Hodgkin’ s disease in first relapse treated by autologous stem cell transplantation: duration of first remission does not predict the transplant outcome. Blood 1997; 90: 594a [Abstract].

    Google Scholar 

  28. Arranz R, Tomas JF, Gil-Fernandez JJ, et al. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin’ s disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998; 21: 779.

    Article  PubMed  CAS  Google Scholar 

  29. Jagganath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 1989; 7: 179.

    Google Scholar 

  30. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous transplantation in Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704.

    PubMed  CAS  Google Scholar 

  31. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2002; 20: 221.

    Article  PubMed  Google Scholar 

  32. André M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Société Francaise de Greffe de Moëlle. J Clin Oncol 1999; 17: 222.

    PubMed  Google Scholar 

  33. Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter a remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Bone Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17: 3101.

    PubMed  CAS  Google Scholar 

  34. Reece DE, Barnett MJ, Shepard JD, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP-16) with or without cisplatin (CBV +1- P) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451.

    PubMed  CAS  Google Scholar 

  35. Lazarus H, Rowlings P, Zhang M, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534.

    PubMed  CAS  Google Scholar 

  36. Josting A, Reiser M, Rueffer U, et al. Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol 2000; 18: 332.

    PubMed  CAS  Google Scholar 

  37. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’ s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478.

    Article  PubMed  CAS  Google Scholar 

  38. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’ s disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630.

    Article  PubMed  Google Scholar 

  39. Diehl V, Franklin J, Sieber M, et al. Dose escalated BEACOPP chemotherapy improves failure free survival in advanced-stage Hodgkin’s disease: updated results of the German Hodgkin’ s Lymphoma Study Group. Blood 2000; 96: 2474a [Abstract].

    Google Scholar 

  40. Straus DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’ s disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173.

    PubMed  CAS  Google Scholar 

  41. Proctor SJ, Taylor P, Donan P, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’ s disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 1991; 27: 624.

    Article  PubMed  CAS  Google Scholar 

  42. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’ s disease. N Engl JMed 1998; 339: 1506.

    Article  CAS  Google Scholar 

  43. Carella AM, Carlier P, Congui A, et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin’s disease in first complete remission after MOPP/AB VD protocol. Bone Marrow Transplant 1991; 8: 99.

    PubMed  CAS  Google Scholar 

  44. Fleury J, Legros M, Colombat P, et al. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin’ s disease. Leuk Lymphoma 1996; 20: 259.

    Article  PubMed  CAS  Google Scholar 

  45. Sureda A, Mataix R, Hernandez-Navarro F, et al. Autologous stem cell transplantation for poor prognosis Hodgkin’ s disease in first complete remission: a retrospective study from the Spanish GEL-TAMO Cooperative Group. Bone Marrow Transplant 1997; 20: 283.

    Article  PubMed  CAS  Google Scholar 

  46. Schmitz M, Hasenclever D, Brosteanu O, et al. Early high-dose therapy to consolidate patients with high-risk Hodgkin’ s disease in first complete remission? Results of an EBMT/GHSG matched-pair analysis. Blood 1995; 86: 439a [Abstract].

    Google Scholar 

  47. Carella AM, Prencipe E, Pungolino E, et al. Twelve years’ experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin’s disease patients in first remission after MOPP/AB VD chemotherapy. Leuk Lymphoma 1996; 21: 63.

    Article  PubMed  CAS  Google Scholar 

  48. Nademanee A, Molina A, Fung H, et al. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced stage Hodgkin’ s disease during first complete or partial remission. Biol Blood Marrow Transplant 1999; 5: 292.

    Article  PubMed  CAS  Google Scholar 

  49. Proctor SJ, Mackie M, Dawson A, et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin’s disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002; 38: 795.

    Article  PubMed  CAS  Google Scholar 

  50. Federico M, Carella A, Brice P, et al. High-dose therapy (HDT) and autologous stem cell transplantation (AS CT) versus conventional therapy for patients with advanced Hodgkin’s disease (HD) responding to initial therapy. Proc Am Soc Clin Oncol 2002; 21: 263a [Abstract].

    Google Scholar 

  51. Saghatchian M, Djeridane M, Escoffre-Barbe M, et al. Very high risk Hodgkin’s disease (HD): ABVd (4 cycles) plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles) (INT-CT) and RT. Four-year results of the GOELAMS H97-GM multi-centric randomized trial. Proc Am Soc Clin Oncol 2002; 21: 263a [Abstract].

    Google Scholar 

  52. Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996; 36: 3.

    Article  PubMed  CAS  Google Scholar 

  53. Mundt AJ, Sibley G, Williams S, Hallahan D, et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1995; 33: 261.

    Article  PubMed  CAS  Google Scholar 

  54. Lancet JE, Rapoport AP, Brasacchio R, et al. Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1998; 22: 265.

    Article  PubMed  CAS  Google Scholar 

  55. Tsang RW, Gospodarowicz MK, Sutcliffe SB, et al. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin’s disease. PMH Lymphoma Group, and Toronto Autologous BMT Group. Eur J Cancer 1999; 35: 73.

    Article  PubMed  CAS  Google Scholar 

  56. Krishnan A, Bhatita S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation: an assessment of risk factors. Blood 2000; 95: 1588.

    PubMed  CAS  Google Scholar 

  57. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’ s lymphoma. J Clin Oncol 1994; 12: 2535.

    Google Scholar 

  58. Guitierrez-Delgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-Hodgkin’s lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant 2001; 28: 455.

    Article  Google Scholar 

  59. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin’ s disease and non-Hodgkin’ s lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648.

    PubMed  CAS  Google Scholar 

  60. Weaver C, Appelbaum F, Peterson F, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiotherapy. J Clin Oncol 1993; 11: 1329.

    PubMed  CAS  Google Scholar 

  61. Reece DE, Nevill TJ, Sayegh A, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP-16–213) (CB V) and CB V plus cisplatin (CB VP) followed by autologous stem cell transplantation in patients with Hodgkin’ s disease. Bone Marrow Transplant 1999; 23: 1131.

    Article  PubMed  CAS  Google Scholar 

  62. The non-Hodgkin’s Lymphoma Classification Project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphomas. Blood 1997;89:3909.

    Google Scholar 

  63. Fisher R, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’ s lymphoma. N Engl J Med 1993; 328: 1002.

    Article  PubMed  CAS  Google Scholar 

  64. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin’ s lymphoma. N Engl J Med 1993;329:987.

    Google Scholar 

  65. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared to salvage therapy in relapses of chemotherapy-sensitive non-Hodgkin’ s lymphoma. N Engl J Med 1995; 333: 1540.

    Article  PubMed  CAS  Google Scholar 

  66. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’ s lymphoma. N Engl J Med 1987; 316: 1493.

    Article  PubMed  CAS  Google Scholar 

  67. Rapoport AP, Lifton R, Constine LS, et al. Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997; 19: 883.

    Article  PubMed  CAS  Google Scholar 

  68. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the PARMA trial. J Clin Oncol 1998; 16: 3264.

    PubMed  CAS  Google Scholar 

  69. Blay J, Gomez F, Sebban C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998; 92: 3562.

    PubMed  CAS  Google Scholar 

  70. Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade non-Hodgkin’s lymphoma in first complete remission. J Clin Oncol 1994; 12: 2543.

    Google Scholar 

  71. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol a groupe d’Étude des lympho- mas de l’Adulte study. J Clin Oncol2000; 18: 3025.

    Google Scholar 

  72. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the Non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796.

    Google Scholar 

  73. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: randomized phase III EORTC study. JNatl Cancer Inst 2001; 93: 22.

    Article  CAS  Google Scholar 

  74. Kaiser U, Uebelacker I, Havemann K, et al. High dose chemotherapy with autologous stem cell transplantation in high grade NHL: first analysis of a randomized multicenter study. Bone Marrow Transplant 1998; 21: S177.

    Google Scholar 

  75. Gianni A, Bregni M, Salvatore S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290.

    Article  PubMed  CAS  Google Scholar 

  76. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472.

    Google Scholar 

  77. Vitolo U, Liberati AM, Deliliers GL, et al. A multicenter randomized trial by the Italian Lymphoma Intergroup (ILI) comparing high dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) vs. intensified chemotherapy MegaCEOP in high risk diffuse large B-cell lymphoma (DLBCL): no difference in outcome and toxicity. Blood 2001; 98: 252b.

    Google Scholar 

  78. Vose JM, Zhang M-J, Philip A, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Bone Marrow Transplant Registry. J Clin Oncol 2001; 19: 406.

    PubMed  CAS  Google Scholar 

  79. Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’ s lymphoma. N Engl J Med 1995; 332: 1045.

    Article  PubMed  CAS  Google Scholar 

  80. Martelli M, Vignetti M, Zinzani P, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytaribine in aggressive non-Hodgkin’ s lymphoma with partial response to front-line chemotherapy: a prospective randomize Italian multicenter study. J Clin Oncol 1996; 14: 534.

    PubMed  CAS  Google Scholar 

  81. MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282.

    CAS  Google Scholar 

  82. Horning SJ. Follicular lymphoma: have we made ant progress? Ann Oncol 2000; 11: 23.

    Article  PubMed  Google Scholar 

  83. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140.

    PubMed  CAS  Google Scholar 

  84. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325.

    PubMed  CAS  Google Scholar 

  85. Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527.

    PubMed  CAS  Google Scholar 

  86. Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1997; 15: 445.

    PubMed  CAS  Google Scholar 

  87. Rohatiner A, Johnson P, Price C, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177.

    PubMed  CAS  Google Scholar 

  88. Schouten HC, Kvaloy S, Sydes M, et al. The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 2000; 11 (suppl 1): 91.

    Article  PubMed  Google Scholar 

  89. Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000; 11: 1585.

    Article  PubMed  CAS  Google Scholar 

  90. Molina A, Nadenamee A, O’ Donnel M, et al. Long-term follow-up and analysis of prognostic factors after high-dose therapy and peripheral blood stem cell autografting in 58 patients with a history of low grade follicular lymphoma. Blood 1999; 94: 171a.

    Google Scholar 

  91. Cao TM, Horning SJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294.

    Article  PubMed  CAS  Google Scholar 

  92. Bastion Y, Brice P, Haioun A, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257.

    PubMed  CAS  Google Scholar 

  93. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma. Bone Marrow Transplant 1998; 21: 383.

    Article  PubMed  CAS  Google Scholar 

  94. Colombat P, Donadio D, Foillard L, et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994; 13: 157.

    PubMed  CAS  Google Scholar 

  95. Voso MT, Martin S, Hohaus S, et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PB SCT). Bone Marrow Transplant 2000; 25: 957.

    Article  PubMed  CAS  Google Scholar 

  96. Seyfarth B, Kuse R, Sonnen R, et al. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol 2001; 80: 398.

    Article  PubMed  CAS  Google Scholar 

  97. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404.

    Article  PubMed  CAS  Google Scholar 

  98. Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780.

    Google Scholar 

  99. Tarella C, Caracciolo D, Corrandini P, et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated up front with high-dose sequential chemotherapy and autograft. Leukemia 2000; 14: 740.

    Article  PubMed  CAS  Google Scholar 

  100. Colombat P, Cornillet P, Deconick E, et al. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant 2000; 26: 971.

    Article  PubMed  CAS  Google Scholar 

  101. Morel P, Laporte J, Noel MP, et al. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995; 9: 576.

    PubMed  CAS  Google Scholar 

  102. Bociek R, Bierman P, Vose J, et al. High dose therapy with autologous hematopoietic stem cell transplantation for patients with low-grade follicular non-Hodgkin’ s lymphoma in first complete or partial remission. Blood 1999; 94: 170a.

    Google Scholar 

  103. Ladetto M, Corrandini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002; 100: 1559.

    Article  PubMed  CAS  Google Scholar 

  104. Colombat P, Foussard C, Bertrand P, et al. Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: first results of the randomized GOELAMNS 064 trial. Blood 2001; 98: 861a.

    Google Scholar 

  105. Acker B, Hoppe RT, Colby TV, et al. Histologic conversion in non-Hodgkin’s lymphomas. J Clin Oncol 1983; 1: 11.

    PubMed  CAS  Google Scholar 

  106. Cullen MH, Lister TA, Bearly RI, et al. Histological transformation of non-Hodgkin’ s lymphoma. Cancer 1979; 44: 645.

    Article  PubMed  CAS  Google Scholar 

  107. Bastion Y, Sebban C, Berger P, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 1587.

    PubMed  CAS  Google Scholar 

  108. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470.

    PubMed  CAS  Google Scholar 

  109. Yuen AR, Kamel OW, Halpern J, et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13: 1726.

    PubMed  CAS  Google Scholar 

  110. Schoeten HC, Bierman PJ, Vaughan WP, et al. Autologous bone marrow transplantation in follicular non-Hodgkin’ s lymphoma before and after histologic transformation. Blood 1989; 74: 2579.

    Google Scholar 

  111. Foran JM, Apostolidis J, Papamichael D, et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single center. Ann Oncol 1998; 9: 865.

    Article  PubMed  CAS  Google Scholar 

  112. Williams CD, Harrison CN, Lister TA, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19: 727.

    PubMed  CAS  Google Scholar 

  113. Chen CI, Crump M, Tsang R, et al. Autotransplants for histologically transformed follicular non-Hodgkin’s lymphoma. Br J Haematol 2001; 113: 202.

    Article  PubMed  CAS  Google Scholar 

  114. Friedberg JW, Neuberg D, Gribben JG, et al. Autologous bone marrow transplantation after histologic transformation of indolent B-cell malignancies. Biol Bone Marrow Transplant 1999; 5: 262.

    Article  CAS  Google Scholar 

  115. Gribben JG, Freedman AS, Neuberg D, et al Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525.

    Article  PubMed  CAS  Google Scholar 

  116. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bd-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449.

    PubMed  CAS  Google Scholar 

  117. Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin’s lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454.

    Google Scholar 

  118. Johnson P, Price C, Smith T, et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798.

    PubMed  CAS  Google Scholar 

  119. Magni M, Di Nichola M, Devizzi L, et al. Successful purging of CD34-containing peripheral blood harvest in mantle cell and indolent lymphoma: evidence for arole of both chemotherapy and rituximab infusion. Blood 2000; 96: 864.

    PubMed  CAS  Google Scholar 

  120. Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’ s lymphoma. Br J Haematol 2000; 109: 729.

    Article  PubMed  CAS  Google Scholar 

  121. Haioun C, Delfau-Larue M, Beaujean F, et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy with autologous peripheral blood stem cell transplantation in B-cell non-Hodgkin’ s lymphoma. Blood 2000; 96: 184a.

    Google Scholar 

  122. Belhadj K, Delfau-Larue M, Elgnoui T, et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell lymphomas. A single institution study. Proc Am Soc Clin Oncol 2002; 21: 285a.

    Google Scholar 

  123. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy, and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229.

    Article  PubMed  CAS  Google Scholar 

  124. Morschhauser F, Recher C, Galoin S, et al. Multicenter, phase II trial to evaluate the efficacy and safety of rituximab in patients suffering from follicular non-Hodgkin’ s lymphoma (FNHL) with residual minimal disease after autologous transplantation of hematopoietic stem cells (M39012 trial). Proc Am Soc Clin Oncol 2002; 21: 267a.

    Google Scholar 

  125. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. J Clin Oncol 1995; 13: 2819.

    Google Scholar 

  126. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based study. J Clin Oncol 1996; 14: 1269.

    PubMed  CAS  Google Scholar 

  127. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1996; 6: 257.

    Google Scholar 

  128. Majlis A, Pugh WH, Rodriguez MA, et al. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997; 15: 1664.

    PubMed  CAS  Google Scholar 

  129. ArgatoffLH, Connors JM, Klasa R7, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067.

    Google Scholar 

  130. Oinonen R, Franssila K, Teerenhovi, et al. Mantle cell lymphoma: clinical features, treatment, and prognosis of 94 patients. Eur J Cancer 1998; 34: 329.

    Article  PubMed  CAS  Google Scholar 

  131. Vandenberghe E, Ruiz de Elvira C, Isaacson P, et al. Does transplantation improve outcome in mantle cell lymphoma (MCL)? A study from the EBMT. Blood 2000; 96: 482a. [Abstract].

    Google Scholar 

  132. Weisenberger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64: 190.

    Article  Google Scholar 

  133. Foran JM, Cunningham D, Coiffier B, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317.

    PubMed  CAS  Google Scholar 

  134. Howard O, Gribben 7G, Neuberg D, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288.

    Article  PubMed  CAS  Google Scholar 

  135. Stewart DA, Vose JM, Weisenberger DD, et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263.

    PubMed  CAS  Google Scholar 

  136. Haas R, Brittinger G, Meusers P, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10: 1975.

    PubMed  CAS  Google Scholar 

  137. Dreger P, von Neuhoff N, Kuse R, et al. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997; 8: 401.

    Article  PubMed  CAS  Google Scholar 

  138. Ketterer N, Salles G, Espinouse D, et al. Intensive therapy with peripheral blood stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8: 701.

    Article  PubMed  CAS  Google Scholar 

  139. Kroger N, Hoffneckht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1999; 21: 55.

    Article  Google Scholar 

  140. Blay 7-Y, Sebban C, Surbiguet C, et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998; 21: 51.

    Article  Google Scholar 

  141. Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998; 22: 645.

    Article  PubMed  CAS  Google Scholar 

  142. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for longterm remission. J Clin Oncol 1998; 16: 13.

    PubMed  CAS  Google Scholar 

  143. Vose JM, Bierman PJ, Weisenberger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000; 6: 640.

    Article  PubMed  CAS  Google Scholar 

  144. Malone JM, Molina A, Stockerl-Goldstein K, et al. High dose therapy and autologous hematopoietic cell transplantation for mantle cell lymphoma: the Stanford/City of Hope experience. Proc Am Soc Clin Oncol 2001; 20: 13a.

    Google Scholar 

  145. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytaribine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 1998; 16: 3803.

    PubMed  CAS  Google Scholar 

  146. Romaguera JE, Dang NH, Hagemeister FB, et al. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL). Blood 2000; 96: 733a. [Abstract].

    Google Scholar 

  147. Decaudin D, Brouse N, Brice P, et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow up study. Bone Marrow Transplant 2000; 25: 251.

    Article  PubMed  CAS  Google Scholar 

  148. Lefere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2000; 16: 587.

    Article  Google Scholar 

  149. Hiddemann W, Dreyling M, Pfreundschuh M, et al. Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of event-free survival in patients with mantle cell lymphoma (MCL): results of a prospective randomized European Intergroup study. Blood 2001; 98: 861a.

    Google Scholar 

  150. Jacquy C, Lambert F, Soree A, et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin’s lymphoma: the case for purging? Bone Marrow Transplant 1999; 23: 681.

    Article  PubMed  CAS  Google Scholar 

  151. Anderson NS, Donovan JW, Boras JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212.

    Google Scholar 

  152. Mangel J, Buckstein R, Imrie K, et al Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29 (suppl 2): 56.

    Article  PubMed  CAS  Google Scholar 

  153. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934.

    Google Scholar 

  154. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158.

    Article  PubMed  CAS  Google Scholar 

  155. Behr TM, Griesinger F, Riggert J, at al. High-dose myeloablative radioimmunotherapy of mantle cell lymphoma with iodine-131-labeled chimeric anti-CD20 antibody C2B 8 and autologous stem cell support. Cancer 2002; 94: 1363.

    Article  PubMed  CAS  Google Scholar 

  156. Wollner N, Burchenal JH, Liebermann PH, et al. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2L2 protocol. Cancer 1979; 44: 1900.

    Article  Google Scholar 

  157. Coleman CN, Picozzi VJ, Cox RS, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1626.

    Google Scholar 

  158. Slater DE, Mertelsmann R, Koriner B, et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 57.

    PubMed  CAS  Google Scholar 

  159. Milpied N, Ifrah N, Kuentz M, et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989; 73: 82.

    Article  PubMed  CAS  Google Scholar 

  160. Santini G, Coser P, Chisesi T, et al. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Ann Oncol 1991; 2: 181.

    Article  PubMed  Google Scholar 

  161. Verdonck LF, Dekker AW, Gast GC, et al. Autologous bone marrow transplantation for adult poor risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992; 10: 644.

    PubMed  CAS  Google Scholar 

  162. Sweetenham JW, Liberti G, Pearce R, et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994; 12: 1358.

    PubMed  CAS  Google Scholar 

  163. Jost LM, Jacky E, Dommann-Scherrer C, et al. Short-term weekly chemotherapy followed by high-dose therapy and autologous bone marrow transplantation for lymphoblastic and Burkitt’ s lymphomas in adult patients. Ann Oncol 1995; 6: 445.

    PubMed  CAS  Google Scholar 

  164. Bouabdallah R, Xerri L, Bardou V-J, et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: A report on 62 patients from a single center. Ann Oncol 1998; 9: 619.

    Article  PubMed  CAS  Google Scholar 

  165. Sweetenham JW, Santini G, Qian W, et al. High-dose therapy and autologous stem-cell transplantation versus conventional consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001; 19: 2927.

    Google Scholar 

  166. Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt’ s and Burkitt-like non-Hodgkin’ s lymphoma outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996; 14: 2465.

    Google Scholar 

  167. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925.

    PubMed  CAS  Google Scholar 

  168. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’ s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264.

    Article  PubMed  CAS  Google Scholar 

  169. Bernstein JL, Coleman CN, Strickler JG, et al. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt’s and non-Burkitt’s types). J Clin Oncol 1986; 4: 847.

    PubMed  CAS  Google Scholar 

  170. Longo Dl, Duffey PL, Jaffe ES, et al. Diffuse small noncleaved-cell, non-Burkitt’ s lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol 1994; 12: 2153.

    Google Scholar 

  171. Soussain C, Patte C, Ostronoff M, et al. Small non-cleaved cell lymphoma and leukemia in adults: a retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85: 664.

    PubMed  CAS  Google Scholar 

  172. Hoelzer D, Ludwig W-D, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1998; 87: 495.

    Google Scholar 

  173. Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 9251. J Clin Oncol 2001; 19: 4014.

    PubMed  CAS  Google Scholar 

  174. Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’ s type adult lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461.

    Google Scholar 

  175. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: the non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909.

    Google Scholar 

  176. Cheng AL, Chen YC, Wang CH, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histologic grades should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989; 7: 725.

    PubMed  CAS  Google Scholar 

  177. Kwak LW, Wilson M, Weiss LM, et al. Similar outcome of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol 1991; 9: 1426.

    PubMed  CAS  Google Scholar 

  178. Armitage JO, Vose JM, Linder J, et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 1989; 7: 1783.

    PubMed  CAS  Google Scholar 

  179. Melnyk A, Rodriguez A, Pugh WC, et al. Evaluation of the Revised European-American Lymphoma Classification confirms clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 1997; 89: 4514.

    PubMed  CAS  Google Scholar 

  180. Vose JM, Peterson C, Bierman PJ, et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin’s lymphomas. Blood 1990; 76: 424.

    PubMed  CAS  Google Scholar 

  181. Blystad AK, Enblad G, Kval¢y S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T-cell lymphomas. Bone Marrow Transplant 2001; 27: 711.

    Article  PubMed  CAS  Google Scholar 

  182. Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766.

    PubMed  CAS  Google Scholar 

  183. Rodriguez J, Caballero A, Gutierrez J, et al. Results of high dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma (PTCL). The Spanish Lymphoma Cooperative Group Experience (GEL/TAMO). Blood 2001; 98: 680a.

    Google Scholar 

  184. Fanin R, Silvestri F, Geromin A, et al. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with F-MACHOP regimen (+/-radiotherapy) and autologous bone marrow transplantation. Blood 1996; 87: 1243.

    PubMed  CAS  Google Scholar 

  185. Deconinck E, Lamy T, Foussard C, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000; 109: 736.

    Article  PubMed  CAS  Google Scholar 

  186. Jagasia M, Stein R, Kinney M, et al. High dose chemotherapy (HDC) and hematopoietic stem cell transplant (HSCT) in peripheral T-cell (PTCL), NK cell, and Ki-1 anaplastic large cell lymphoma. Proc Am Soc Clin Oncol 2001; 20: 294a.

    Google Scholar 

  187. Bakr M, Ketterer N, Rosselet A, et al. High-dose chemotherapy and autologous blood stem cell support in patients with aggressive T-cell lymphomas. Proc Am Soc Clin Oncol 2002; 21: 1147.

    Google Scholar 

  188. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin’ s lymphoma. Biol Blood Marrow Transplant 1996; 2: 76.

    PubMed  CAS  Google Scholar 

  189. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353.

    Article  PubMed  CAS  Google Scholar 

  190. Majolino I, Pearce R, Taghipour G, et al. Peripheral blood stem cell transplantation versus autologous bone marrow transplantation in Hodgkin’ s and non-Hodgkin’s lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509.

    PubMed  CAS  Google Scholar 

  191. Brice P, Marolleau JP, Pautier P, et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leuk Lymphoma 1996; 22: 449.

    Article  PubMed  CAS  Google Scholar 

  192. Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial of to compare filgrastim-mobilised peripheral-blood progenitor-cell transplantation versus autologous bone marrow transplantation in patients with Hodgkin’ s and on-Hodgkin’s lymphoma. J Clin Oncol 1997; 15: 5.

    PubMed  CAS  Google Scholar 

  193. Vellenga, E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life, and cost reduction compared with bone marrow transplantation: Hovon 22 study. Br J Haematol 2001; 114: 319.

    Article  PubMed  CAS  Google Scholar 

  194. Perry AR, Peniket AJ, Watts MJ, et al. Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin’ s disease: equivalent survival outcome in a single-centre matched-pair analysis. Br J Haematol 1999; 105: 280.

    Article  PubMed  CAS  Google Scholar 

  195. Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059.

    Google Scholar 

  196. Darrington DL, Vose JM, Anderson JA, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527.

    Google Scholar 

  197. Traweek ST, Slovak ML, Nademanee A, et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma. Blood 1994; 84: 957.

    PubMed  CAS  Google Scholar 

  198. André M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease. Blood 1998; 92: 1933.

    PubMed  Google Scholar 

  199. Miller JS, Arthur DC, Litz CE, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780.

    PubMed  CAS  Google Scholar 

  200. Chao NJ, Nademanee AP, Long GD, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin’s disease. J Clin Oncol 1991; 9: 1575.

    PubMed  CAS  Google Scholar 

  201. Milligan D, Ruiz de Elvira M, Goldstone A, et al. Secondary leukemia and myelodysplasia after autografting for lymphomas. Blood 1998; 92: 493a.

    Google Scholar 

  202. van Leeuwen F, Klokman W, van’t Veer M, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487.

    PubMed  Google Scholar 

  203. Swerdlow A, Barber J, Hudson G, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation of age to treatment. J Clin Oncol 2000; 18: 498.

    PubMed  CAS  Google Scholar 

  204. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin’s disease. NEngl J Med 1988; 318: 76.

    Article  CAS  Google Scholar 

  205. Oddou S, Vey N, Viens P, et al. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: six cases in a cohort of 171 patients from a single institution. Leuk Lymphoma 1998; 31: 187.

    Article  PubMed  CAS  Google Scholar 

  206. Jones RJ, Ambinder RF, Piantadosi S, et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1998; 77: 649.

    Google Scholar 

  207. van Biesen KW, De Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977.

    Article  Google Scholar 

  208. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’ s lymphoma: a case-controlled analysis from the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690.

    PubMed  CAS  Google Scholar 

  209. Rhondon G, Giralt Sa, Huh Y, et al. Graft-versus-leukemia after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669.

    Google Scholar 

  210. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after bone marrow transplantation. J Clin Oncol 1997; 15: 433.

    PubMed  Google Scholar 

  211. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludaribine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817.

    Google Scholar 

  212. Bierman PJ, Sweetenham JW, Loberiza F, et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin’ s lymphoma (NHL): comparison with allogeneic and autologous transplants suggests a role for purging. Proc Am Soc Clin Oncol 2001; 20: 5a.

    Google Scholar 

  213. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous bone marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342.

    Google Scholar 

  214. Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’ s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291.

    PubMed  CAS  Google Scholar 

  215. Gajeweski JL, Phillip T, Carella A, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996; 14: 572.

    Google Scholar 

  216. Akpek G, Ambinder SP, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 2001; 19: 4314.

    PubMed  CAS  Google Scholar 

  217. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Bone Marrow Transplant 1997; 20: 369.

    Article  PubMed  CAS  Google Scholar 

  218. Mendoza E, Territo M, Schiller G, et al. Allogeneic bone marrow transplantation for Hodgkin’ s and non-Hodgkin’ s lymphoma. Bone Marrow Transplant 1995; 15: 299.

    PubMed  CAS  Google Scholar 

  219. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1998; 92: 1832.

    PubMed  Google Scholar 

  220. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999; 34: 129.

    PubMed  CAS  Google Scholar 

  221. van Biesen K, Khouri IF, Giralt S, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13: 1096.

    Google Scholar 

  222. Mandigers C, Raemaekers J, Schattenberg A, et al. Allogeneic bone marrow transplantation with T-celldepleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin’s lymphoma. Br J Haematol 1998; 100: 198.

    Article  PubMed  CAS  Google Scholar 

  223. Stein RS, Greer JP, Goodman S, et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved lymphoma of follicular center origin. Bone Marrow Transplant 1999; 23: 227.

    Article  PubMed  CAS  Google Scholar 

  224. Toze CL, Shepherd JD, Connors JM, et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 605.

    Article  PubMed  CAS  Google Scholar 

  225. Forrest D, Matheson K, Couban S, et al. High-dose therapy and allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma. Blood 2001; 98: 408a.

    Google Scholar 

  226. Appelbaum FR, Sullivan KM, Buckner CD, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340.

    PubMed  CAS  Google Scholar 

  227. Van Biesen KW, Mehra RC, Giralt SA, et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response toxicity, and survival depend on disease histology. Am J Med 1996; 100: 299.

    Article  Google Scholar 

  228. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic transplantation in patients with non-Hodgkin’s lymphoma. Blood 1994; 84: 1050.

    PubMed  CAS  Google Scholar 

  229. Stein RS, Greer JP, Goodman S, et al. Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin’s lymphoma. Leuk Lymphoma 2001; 41: 343.

    Article  PubMed  CAS  Google Scholar 

  230. Khouri IF, Lee M-S, Romaguera J, et al. Allogeneic hematopoietic transplantation for mantle cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293.

    Article  PubMed  CAS  Google Scholar 

  231. Sohn SK, Bensinger W, Holmberg L, et al. High-dose chemotherapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: the Seattle experience. Proc Am Soc Clin Oncol 1997; 17: 17a. [Abstract].

    Google Scholar 

  232. Molina A, Nadenamee A, O’Donnell MR, et al. Autologous and allogeneic stem-cell transplantation for poor-risk mantle cell lymphoma: the City of Hope experience. Blood 1998; 92: 459a. [Abstract].

    Google Scholar 

  233. McSweeney PA, Niederweiser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390.

    Article  PubMed  CAS  Google Scholar 

  234. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419.

    Google Scholar 

  235. Perez-Simon JA, Kottaridis PD, Martino, et al. Reduced intensity conditioning (RIC) allogeneic transplantation with or without CAMPATH-1H: comparison between two prospective studies in patients with lymphoproliferative disorders. Blood 2001; 98: 743a. [Abstract].

    Google Scholar 

  236. Branson K, Chopra R, Panagiotis D, et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022.

    Article  PubMed  Google Scholar 

  237. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595.

    Article  PubMed  CAS  Google Scholar 

  238. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as the treatment of resistant Hodgkin’ s disease and non-Hodgkin’ s lymphoma. J Clin Oncol 2000; 18: 3918.

    PubMed  CAS  Google Scholar 

  239. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Blood 2002; 100; 4310.

    Article  PubMed  CAS  Google Scholar 

  240. Khouri IF, Saliba RM, Lee M-S, et al. Nonablative allogeneic stem cell transplantation for non-Hodgkin’s lymphoma (NHL): improved outcome with low incidence of acute GVHD and treatment related mortality. Blood 2001; 98: 416a. [Abstract].

    Google Scholar 

  241. Spitzer TR, McAfee SL, Dey BR, et al. Durable progression free survival (PFS) following non-myeloablative bone marrow transplantation for chemorefractory diffuse large B-cell lymphoma (B-LCL). Blood 2001; 98: 2813a. [Abstract].

    Google Scholar 

  242. Bertz H, Illerhaus G, Veelken H, et al. Allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory lymphomas: a comparison of high-dose conventional conditioning versus fludaribinebased reduced-intensity regimens. Ann Oncol 2002; 13: 135.

    Article  PubMed  CAS  Google Scholar 

  243. Porter Dl, Luger SM, Duffy KM, et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 230.

    Article  Google Scholar 

  244. Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral-blood stem cell transplantation using a fludaribinebased low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021.

    Article  PubMed  CAS  Google Scholar 

  245. Garcia-Marco, JA, Cabrera R, Perez-Sanz N, et al. Analysis of graft-versus-malignancy effect following nonmyeloabaltive stem cell transplantation in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Blood 2001; 98: 5237a. [Abstract].

    Google Scholar 

  246. Hou 7W, Fowler DH, Wilson W, et al. Potent graft-versus-lymphoma effect after a non-myeloablative stem cell transplant in refractory non-Hodgkin’s lymphoma: role of rapid complete donor chimerism. Blood, 2001; 98: 1696a. [Abstract].

    Google Scholar 

  247. Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653.

    Article  PubMed  CAS  Google Scholar 

  248. Mohty M, Fegeux N, Exbrayat C, et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 2001; 28: 335.

    Article  PubMed  CAS  Google Scholar 

  249. Corrandini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75.

    Article  Google Scholar 

  250. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 3: 1071.

    Article  Google Scholar 

  251. Anderlini P, Giralt S, Anderson B, et al. Allogeneic stem cell transplantation with fludaribine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin’s disease. Bone Marrow Transplant 2000; 26: 615.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Thomas J. Kenney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Sweetenham MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kenney, T.J., Sweetenham, J.W. (2004). Stem Cell Transplantation for Hodgkin’s and Non-Hodgkin’s Lymphomas. In: Soiffer, R.J. (eds) Stem Cell Transplantation for Hematologic Malignancies. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-733-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-733-8_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6588-5

  • Online ISBN: 978-1-59259-733-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation